$1.12 Billion is the total value of Sofinnova Investments, Inc.'s 144 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 56.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | Sell | Ascendis Pharma A/Sordinary shares | $175,698,000 | -46.7% | 2,479,514 | -50.0% | 15.66% | -25.5% |
| Sell | Nucana Biomedordinary shares | $99,680,000 | -34.4% | 4,000,000 | -50.0% | 8.89% | -8.3% | |
| OBSV | Sell | ObsEva SA | $85,636,000 | -40.5% | 4,749,623 | -50.0% | 7.63% | -16.8% |
| AMRN | Sell | Amarinordinary shares | $84,739,000 | +312.8% | 5,208,306 | -21.6% | 7.55% | +477.1% |
| NTRA | Sell | Natera | $74,227,000 | -36.4% | 3,100,560 | -50.0% | 6.62% | -11.1% |
| PRNB | New | Principia Biopharmawarrant(s) | $59,556,000 | – | 2,059,146 | +100.0% | 5.31% | – |
| YMAB | New | Y-mAbs Therapeutics, Inc | $55,890,000 | – | 2,104,278 | +100.0% | 4.98% | – |
| CHRS | Sell | Coherus BioSciences | $47,326,000 | -41.6% | 2,868,221 | -50.4% | 4.22% | -18.3% |
| MRUS | Sell | Merus N.V. | $38,711,000 | -56.6% | 1,961,039 | -50.0% | 3.45% | -39.4% |
| BOLD | Sell | Audentes Therapeutics | $36,963,000 | -48.2% | 933,640 | -50.0% | 3.30% | -27.6% |
| ONCE | Sell | Spark Therapeutics | $26,253,000 | -67.0% | 481,270 | -50.0% | 2.34% | -53.9% |
| KNSA | Sell | Kiniksa Pharmaceuticals, Ltd | $23,529,000 | -26.5% | 922,700 | -50.0% | 2.10% | +2.7% |
| ACRS | Sell | Aclaris Therapeutics | $22,353,000 | -63.6% | 1,539,480 | -50.0% | 1.99% | -49.2% |
| SNY | New | Sanofi SAadr | $18,438,000 | – | 412,746 | +100.0% | 1.64% | – |
| AGN | Sell | Allergan plc | $18,290,000 | -10.8% | 96,021 | -22.0% | 1.63% | +24.6% |
| NCNA | Sell | Nucana Biomed | $16,613,000 | -34.4% | 666,666 | -50.0% | 1.48% | -8.4% |
| PBYI | Buy | Puma Biotechnology Inc | $15,444,000 | +282.1% | 336,835 | +393.0% | 1.38% | +433.7% |
| ETTX | New | Entasis Therapeutics Holdings Inc. | $12,840,000 | – | 1,180,178 | +100.0% | 1.14% | – |
| ITRM | Sell | Iterum Therapeutics | $11,438,000 | -69.6% | 1,726,514 | -50.0% | 1.02% | -57.5% |
| RIGL | Buy | Rigel Pharmaceuticals Inc | $10,467,000 | +47.5% | 3,260,931 | +30.1% | 0.93% | +106.0% |
| APLS | Sell | Apellis Pharmaceuticals, Inc | $9,772,000 | -63.9% | 549,580 | -55.4% | 0.87% | -49.6% |
| AZN | Sell | AstraZeneca PLCadr | $9,520,000 | -25.5% | 240,608 | -33.9% | 0.85% | +4.2% |
| HRTX | Buy | Heron Therapeutics Inc | $9,356,000 | -15.6% | 295,589 | +3.6% | 0.83% | +18.0% |
| ALXN | Sell | Alexion Pharmaceuticals Inc | $9,085,000 | -52.9% | 65,360 | -57.9% | 0.81% | -34.1% |
| TSRO | New | TESARO Inc | $8,725,000 | – | 223,675 | +100.0% | 0.78% | – |
| SYBX | Sell | Synlogic Inc. (fmrly Mirna) | $8,170,000 | -27.7% | 574,972 | -50.0% | 0.73% | +1.0% |
| SVRA | Buy | Savara Inc | $7,793,000 | +143.2% | 698,225 | +146.6% | 0.70% | +240.7% |
| AZN | New | AstraZeneca PLCcall | $7,652,000 | – | 193,400 | +100.0% | 0.68% | – |
| EXEL | New | Exelixis Inc | $7,151,000 | – | 403,594 | +100.0% | 0.64% | – |
| ANAB | New | AnaptysBio Inc | $6,946,000 | – | 69,615 | +100.0% | 0.62% | – |
| ADMS | Buy | Adamas Pharmaceuticals Inc | $6,922,000 | -14.3% | 345,756 | +10.6% | 0.62% | +19.8% |
| AIMT | Sell | Aimmune Therapeutics Inc | $6,064,000 | -45.5% | 222,295 | -46.2% | 0.54% | -23.7% |
| CHMA | Sell | Chiasmawarrant(s) | $5,869,000 | +20.0% | 1,767,102 | -50.0% | 0.52% | +67.6% |
| CPRX | Sell | Catalyst Pharmaceuticals Inc | $5,858,000 | +16.5% | 1,549,552 | -3.8% | 0.52% | +62.6% |
| FOLD | New | Amicus Therapeutics Inc | $5,392,000 | – | 445,969 | +100.0% | 0.48% | – |
| DERM | Buy | Dermira Inc | $5,399,000 | +46.0% | 495,293 | +23.2% | 0.48% | +103.8% |
| KDMN | Sell | Kadmon Holdings Incwarrant | $5,152,000 | -28.5% | 1,842,502 | -10.5% | 0.46% | -0.2% |
| BHVN | New | Biohaven Pharmaceutical Holding Company Ltd | $4,996,000 | – | 133,066 | +100.0% | 0.44% | – |
| SRPT | Sell | Sarepta Therapeutics Inc | $4,832,000 | -31.5% | 29,915 | -44.0% | 0.43% | -4.2% |
| RYTM | Buy | Rhythm Pharmaceuticals Inc | $4,646,000 | -4.0% | 159,302 | +2.9% | 0.41% | +34.0% |
| KURA | Buy | Kura Oncology Inc | $4,329,000 | +28.4% | 247,385 | +33.6% | 0.39% | +79.5% |
| BPMC | Sell | Blueprint Medicines Corp | $4,008,000 | -37.9% | 51,339 | -49.5% | 0.36% | -13.3% |
| FOMX | Sell | Foamix Pharmaceuticals Ltd | $3,832,000 | +1.4% | 668,619 | -11.4% | 0.34% | +41.9% |
| CLSD | Buy | Clearside Biomedical Inc | $3,732,000 | -26.9% | 606,914 | +27.1% | 0.33% | +2.1% |
| New | Molecular Partners AG | $3,248,000 | – | 144,960 | +100.0% | 0.29% | – | |
| New | MorphoSys AG | $3,208,000 | – | 30,000 | +100.0% | 0.29% | – | |
| CNAT | Sell | Conatus Pharmaceuticals Inc | $3,126,000 | -22.9% | 538,915 | -43.1% | 0.28% | +7.7% |
| EPZM | New | Epizyme Inc | $3,087,000 | – | 291,318 | +100.0% | 0.28% | – |
| OTIC | Sell | Otonomy Inc | $2,716,000 | -34.7% | 987,778 | -8.5% | 0.24% | -8.7% |
| EDGE | Sell | Edge Therapeutics | $2,339,000 | -60.2% | 2,852,711 | -50.0% | 0.21% | -44.3% |
| SBPH | New | Spring Bank Pharmaceuticals Inc | $2,285,000 | – | 189,646 | +100.0% | 0.20% | – |
| ARQL | New | ArQule Inc | $2,187,000 | – | 386,271 | +100.0% | 0.20% | – |
| FATE | New | Fate Therapeutics Inc | $1,709,000 | – | 104,891 | +100.0% | 0.15% | – |
| ESPR | Sell | Esperion Therapeutics Inc | $1,624,000 | -75.1% | 36,599 | -78.0% | 0.14% | -65.2% |
| SNDX | Buy | Syndax Pharmaceuticals Inc | $1,398,000 | +79.2% | 173,112 | +56.0% | 0.12% | +150.0% |
| ADRO | Sell | Aduro Biotech Inc | $1,393,000 | -25.2% | 189,579 | -28.8% | 0.12% | +4.2% |
| ADAP | New | Adaptimmune Therapeutics PLCadr | $1,220,000 | – | 89,919 | +100.0% | 0.11% | – |
| HSGX | Sell | Histogenics | $1,132,000 | -89.1% | 2,077,040 | -50.0% | 0.10% | -84.7% |
| KALA | Sell | Kala Pharmaceuticals Inc | $944,000 | -79.5% | 95,655 | -71.5% | 0.08% | -71.4% |
| OMED | Sell | OncoMed Pharmaceuticals Inc | $839,000 | -21.9% | 395,744 | -14.9% | 0.08% | +10.3% |
| EARS | Sell | Auris Medical Holding AGwarrant(s) | $0 | – | 140,000 | -50.0% | 0.00% | – |
| FTSV | Exit | Forty Seven Inc | $0 | – | -23,700 | -100.0% | -0.02% | – |
| Exit | Innate Pharma SA | $0 | – | -110,788 | -100.0% | -0.04% | – | |
| CCXI | Exit | ChemoCentryx Inc | $0 | – | -68,258 | -100.0% | -0.06% | – |
| CALA | Exit | CALITHERA BIOSCIENCES INC | $0 | – | -327,845 | -100.0% | -0.10% | – |
| AMAG | Exit | AMAG PHARMACEUTICALS INC | $0 | – | -157,206 | -100.0% | -0.20% | – |
| RETA | Exit | REATA PHARMACEUTICALS INC-A | $0 | – | -99,216 | -100.0% | -0.22% | – |
| SPPI | Exit | SPECTRUM PHARMACEUTICALS INC | $0 | – | -187,453 | -100.0% | -0.25% | – |
| PTCT | Exit | PTC THERAPEUTICS INC | $0 | – | -140,183 | -100.0% | -0.30% | – |
| BLUE | Exit | BLUEBIRD BIO INC | $0 | – | -61,078 | -100.0% | -0.61% | – |
| GWPH | Exit | GW Pharmaceuticals PLCamerican depositary shares | $0 | – | -69,567 | -100.0% | -0.62% | – |
| ICPT | Exit | Intercept Pharmaceuticals Inc | $0 | – | -117,822 | -100.0% | -0.63% | – |
| CRSP | Exit | CRISPR THERAPEUTICS AGput | $0 | – | -220,600 | -100.0% | -0.83% | – |
| CELG | Exit | CELGENE CORP | $0 | – | -203,413 | -100.0% | -1.03% | – |
| Exit | Amarinseries a preferred stock | $0 | – | -7,773,436 | -100.0% | -1.53% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Crestline Management, LP #1
- Blackstone Alternative Asset Management L.P. #2
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.